Hear failure has been divided into three subgroups including heart failure reduced EF, heart failure mildly reduced EF, heart failure<unk>  EF. HFrEF is defined when LVEF≤ 40% and significant LV systolic dysfunction. Patients with a LVEF between 41% and 49% have mildly reduced LV systolic function or HFmrEF. Patients with<unk><unk> s between 40-50%  may benefit from similar therapies to those with LVEF≤ 40%. HFpEF is explained in the presence of  symptoms and signs of HF, and evidence of structural and/or functional cardiac abnormalities and/or raised natriuretic peptides (NPs), and LVEF≥ 50%. Patients with non-cardiovascular disease including anaemia, pulmonary, renal, thyroid, or hepatic disease may mimic symptoms and signs of HF, but in the absence of cardiac dysfunction, they are not diagnosed for HF. Neverthless, these disorders can coexist with HF and exacerbate the HF syndrome.
Congestive heart failure Treatment of Heart failure with preserved ejection fraction
Congestive heart failure treatment of patients with current or prior symptoms of heart failure 
Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction
Congestive heart failure positive inotropics
Right heart failure future or investigational therapies
Dilated cardiomyopathy medical therapy
Coronary artery disease treatment in diabetics
Chronic renal failure secondary prevention